社区资讯

Community information

我们在《柳叶刀》子刊EbioMedicine上发表文章:膀胱癌新辅助化疗生物标志物的研究

时间 : 2018-06-20


EBioMedicine. 2018 Sep;35:198-203. doi: 10.1016/j.ebiom.2018.06.011. Epub 2018 Jun 22.

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.

Yang Z, Zhang R, Ge Y, Qin X, Kang X, Wang Y, Zhang X, Song C, Quan X, Wang H, Chen H, Li C.

1.jpg

Abstract

The administration of neoadjuvant chemotherapy (NAC) preceding radical cystectomy benefits overall survival for patients with muscle-invasive bladder cancer (MIBC). However, the relationship between the genetic profiling of MIBC and NAC response remains unclear. Here, a mutation panel of six cancer-associated genes (TSC1, FGFR3, TERT, TP53, PIK3CA and ERBB2) and an immunohistochemistry (IHC) panel containing eight bladder cancer (BC) biomarkers (EGFR, RRM1, PD-L1, BRCA1, TUBB3, ERCC, ERCC1, aberrantly glycosylated integrin α3β1 (AG) and CK5/6) were developed. BC samples from patients who showed a pathologic response (n = 39) and non-response (n = 13) were applied to the panel analysis. ERBB2, FGFR3 and PIK3CA exclusively altered in the responders group (19/39, 48.7%), in which FGFR3 mutations were significantly enriched in patients with a response in the cohort (14/39, 35.9%; P = 0.01). Additionally, strong expression of ERCC1 was associated with a pathologic response (P = 0.01). However, positive lymph node metastasis (P < 0.01) and lymph-vascular invasion (LVI) (P = 0.03) were correlated with a non-response. Overall, the data show that FGFR3 mutations and elevated expression of ERCC1 in MIBCs are potential predictive biomarkers of the response to NAC.

KEYWORDS: Bladder cancer; ERCC1; FGFR3; Neoadjuvant chemotherapy

PMID: 29941343 PMCID: PMC6154770 DOI: 10.1016/j.ebiom.2018.06.011


2018 版权所有 ©️ 谷雨中科(北京)医疗科技有限公司 京ICP备18001969号-2